Truth or Dare
Bradley Crown is working hard to become a student newspaper reporter. While he is trying to get a front-page story, he faces decisions regarding managing his CF treatment. Find out if he ignores or faces the challenge, and how he takes control.
Click below to launch the interactive comic book experience.
You can download a PDF of Truth or Dare by clicking here.
After reading the story above, find out what happened after Bradley Crown's adventure, in this edition of the Student Spectator.
Indication and Usage
Daily administration of Pulmozyme® (dornase alfa) Inhalation Solution along with standard therapies is indicated in the management of cystic fibrosis patients to improve lung function. In patients with a forced vital capacity (volume of air exhaled with maximum effort and speed) greater than or equal to 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring the administration of injectable antibiotics. In our pivotal study, safety and efficacy of daily administration has not been studied in patients beyond 12 months.
Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients
Pulmozyme should be used along with standard therapies for cystic fibrosis
When starting Pulmozyme therapy, patients may experience change in or loss of their voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose
These side effects are usually mild and short-lived
The effect of Pulmozyme on exercise tolerance has not been established in adults and children
For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.
